Immunosuppressants, Organ Transplants, and the Potential of Regenerative Medicine05 Oct 2010 • by Natalie Aster
LONDON – MarketPublishers Ltd announces that new report “Immunosuppressants, Organ Transplants, and the Potential of Regenerative Medicine: Market Size, Competitive Landscape, and Pipeline Analysis" prepared by Business Insights is available in its catalogue.
This research study generates a deep insight into the segment of regenerative medicine, immunosuppressants and organ transplants development. It encompasses an in-depth analysis of the major classes of immunosuppressants, examining how treatment protocols have evolved over the last ten years; analyses potential clinical advances of the developments and trends; assesses the potential impact of regenerative medicine (stem cells) on the market, with drivers and resistors to market growth. Ten-year forecasts of the number of transplants by organ and country, including estimates of the size of the maintenance populations are opened up within the framework of the present report.
Title: Immunosuppressants, Organ Transplants, and the Potential of Regenerative Medicine: Market Size, Competitive Landscape, and Pipeline Analysis
Published: August, 2010
Report Sample Abstract
Based on data from approximately 25,000 patients, the most commonly used maintenance immunosuppressant at discharge in 2007 was tacrolimus, used in 89% of liver transplants, 87% of lung transplants, 83% of kidney transplants and 63% of heart transplants. Mycophenolate mofetil (MMF) and mycophenolic acid (MPA) were the most commonly used adjunctive agents, used in around 90% of kidney, 88% of heart, 70% of liver and 60% of lung transplants. The mTOR inhibitors, sirolimus and everolimus, were used in around 3-4% of heart and kidney transplants and 2% of liver transplants, most often in combination with a calcineurin inhibitor.
Growth in the transplantation market is expected to decline in the seven major markets from 2010 onwards, as sales of the top-selling brands, Prograf, CellCept and Neoral, begin to decline due to increased generic competition. In Europe, Astellas will be able to protect some Prograf sales through the ongoing uptake of Advagraf, although Prograf will still be vulnerable to varying levels of generic erosion. Growth in the mTOR inhibitor class is expected to be modest, as although they have nephrotoxicity sparing potential, clinical results to date have been mixed. While modern immunosuppressive regimes have led to important improvements in short-term graft-survival rates, these have not been accompanied by a proportionate increase in long-term graft survival. There remains a need for novel agents that can reduce the incidence of acute and chronic rejection: however, achieving large increases in long-term graft-survival will be challenging.
To order the report or ask for free sample pages contact email@example.com
Mrs. Alla Martin
Tel: +44 208 144 6009
Fax: +44 207 900 3970